Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study

Table 2 Comparison of serum phosphorus response to baseline phosphorus at each visit (n = 94)

Visit	mean ± SD	P value (compared to baseline)
Serum phosphorus (mg/dL)
Per protocol population (n = 94)
Screening visit: Day 7 to Day 1	7.62 ± 2.02	-
Follow-up visit: Day 28	6.37 ± 2.33	P < 0.05
Follow-up visit: Day 56	5.49 ± 2.19	P < 0.05
End of study visit: Day 84	5.13 ± 1.88	P < 0.05
Change from baseline at Day 28	1.25 ± 1.55	P < 0.05
Change from baseline at Day 56	2.19 ± 2.07	P < 0.05
Change from baseline at Day 84	2.49 ± 2.13	P < 0.05

P value was analysed using Wilcoxon test.